AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04079140
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
Trial: NCT01763840
Drug: Contrast enhanced Ultrasound
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound, then contrast enhanced ultrasound.
Trial: NCT00031902
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02587273
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
Trial: NCT02496052
Drug: estradiol valerate tablets+dydrogesterone Tablets
RxNorm normalized name: dydrogesterone / estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral estradiol valerate tablets+dydrogesterone Tablets
Trial: NCT02369172
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02860429
Drug: Cinobufacini injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
Trial: NCT02860429
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
Trial: NCT02551549
Drug: CD101 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antifungal
Trial: NCT02551549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT02093195
Drug: Symbicort turbuhaler
RxNorm normalized name: Symbicort Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01821560
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00620503
Drug: Proellex 25 mg formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 25 mg Proellex capsule formulation B administered both fed and fasted
Trial: NCT00811486
Drug: Spironolactone and conivaptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
Trial: NCT00610480
Drug: 1st visit Optive, then 2nd visit Systane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.
Trial: NCT00610480
Drug: 1st visit Systane, then 2nd visit Optive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.
Trial: NCT04326426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02908191
Drug: ABI-H0731
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02908191
Drug: Placebo for ABI-H0731
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01458535
Drug: ABT-450
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT01458535
Drug: ABT-267
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT02719093
Drug: recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT04549168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matched to lemborexant 10 mg tablet.
Trial: NCT00470301
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00470301
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02825979
Drug: Anti-Arrhythmic Drug Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
Trial: NCT03267199
Drug: Thrombolytic
RxNorm normalized name: THROMBOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy
Trial: NCT01564680
Drug: Lornoxicam
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg at skin closure and 8 mg 12 hours postoperative
Trial: NCT02464176
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine will be used in lumbar plexus nerve block mixture.
Trial: NCT04590482
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo given twice daily for 2 days followed by 800mcg misoprostol vaginally to induce abortion
Trial: NCT01675167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Buccal Film twice daily
Trial: NCT00167219
Drug: Preparative Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Busulfan~* Cyclophosphamide~* Mesna~* Melphalan~* Anti-thymocyte Globulin (ATG)
Trial: NCT01152931
Drug: Lumefantrine + Artemether
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
Trial: NCT00594568
Drug: LY450139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily
Trial: NCT00594568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily
Trial: NCT01440608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
Trial: NCT03140813
Drug: AZD7325 (High-Dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg PO BID
Trial: NCT03140813
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
Trial: NCT02042872
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
Trial: NCT02103673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention drug: placebo by mouth. Duration: 6 weeks
Trial: NCT03696459
Drug: JNJ-53718678, 2000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
Trial: NCT03696459
Drug: JNJ-53718678, 3000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
Trial: NCT03696459
Drug: JNJ-53718678, 4500 mg or Dose to be decided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
Trial: NCT03696459
Drug: JNJ-53718678 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
Trial: NCT01214096
Drug: rhNRG-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Administration:0.6ug/kg/day for 10days
Trial: NCT02487459
Drug: AP1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dimerizer drug administered to treat GVHD
Trial: NCT01214096
Drug: rhNRG-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Administration 1.2ug/kg/day for 10 days
Trial: NCT01214096
Drug: rhNRG-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein infusion:0.6ug/kg/day for 10 days
Trial: NCT01214096
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
Trial: NCT01574183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to 40 mg capsule daily
Trial: NCT02515175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline
Trial: NCT01556659
Drug: Absence of vitamin K antagonist
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual anti-platelet therapy
Trial: NCT01180634
Drug: Aeroquin
RxNorm normalized name: Enroquin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Solution
Trial: NCT01180634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation Solution
Trial: NCT02482818
Drug: Control-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A control substance, Lactose is administered in place of Pregabalin.
Trial: NCT02712047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
Trial: NCT00826462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection with sodium chloride at start and at 3 weeks
Trial: NCT00826462
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg bid for 14 days
Trial: NCT02145949
Drug: Placebo (Alanine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery \[surgery = primary total knee arthroplasty\]
Trial: NCT00153751
Drug: Holopon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: holopon
Trial: NCT00436345
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
Trial: NCT03609606
Drug: D013, D326 and D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
Trial: NCT00103376
Drug: Androgen Receptor Antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given orally daily for 3 months
Trial: NCT04726631
Drug: regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: is a type of short-acting insulin.
Trial: NCT01296672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every day by mouth for 3 months
Trial: NCT01464060
Drug: PPI, amoxicillin, metronidazole and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
Trial: NCT01464060
Drug: PPI, amoxicillin, metronidazole and clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
Trial: NCT03378713
Drug: GROUP 1: Long testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application
Trial: NCT03378713
Drug: GROUP 2: Short testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
Trial: NCT01568255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo at 50,000IU for 8 weeks
Trial: NCT03047889
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy for advanced/metastatic breast cancer
Trial: NCT00250965
Drug: intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
Trial: NCT03378713
Drug: GROUP 3: Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The COS starts directly on the second day of the cycle without prior medication.
Trial: NCT03106740
Drug: Minocycline Hydrochloride 100mg Capsule
RxNorm normalized name: minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 100mg will be administered by mouth daily for 2 weeks
Trial: NCT00093379
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825 mg/m\^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
Trial: NCT00888186
Drug: levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intestinal gel, for continuous daytime infusion
Trial: NCT00133003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
Trial: NCT03082625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01790997
Drug: DLBS1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of DLBS1033 490 mg thrice daily, after meal
Trial: NCT00694148
Drug: NT 201
RxNorm normalized name: Fluarix Quadrivalent 2013-2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Botulinum neurotoxin type A, free of complexing proteins~Detailed described in study protocol
Trial: NCT04402944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 2.5 mL BID
Trial: NCT04209166
Drug: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
Trial: NCT04209166
Drug: SSRIs/SNRIs+Mood Stabilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with Mood Stabilizer combined with Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors.
Trial: NCT01548573
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01548573
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT02751372
Drug: BAY 987517
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
Trial: NCT00326339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo PO bid
Trial: NCT01694407
Drug: Placebo Vaginal Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Tablet containing no drug
Trial: NCT00459186
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for two weeks
Trial: NCT00795210
Drug: Growth Hormone Releasing Hormone
RxNorm normalized name: Growth hormone releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tesamorelin (GHRH) 2mg SC QD x 2 weeks
Trial: NCT00974480
Drug: Tretinoin (Rejuva-A)
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.025% cream.
Trial: NCT03883841
Drug: Iron Sucrose Solution for Injection
RxNorm normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of iron sucrose
Trial: NCT00709865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT05709938
Drug: Glargine and regular insulin versus NPH and regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening.
Trial: NCT00144859
Drug: SB681323
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02920242
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo tablet administered orally
Trial: NCT02802267
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04462588
Drug: Cipro 400 MG in 200 ML Injection
RxNorm normalized name: Cipro 400 MG in 200 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical tratment group
Trial: NCT04462588
Drug: Flagyl I.V. RTU
RxNorm normalized name: Flagyl I.V. RTU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical tratment group
Trial: NCT03825861
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
Trial: NCT02460601
Drug: Qizhiweitong granule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00124709
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional corticosteroid-based treatment
Trial: NCT00122954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soybean oil with 1% fish oil at a daily dose of 6 grams
Trial: NCT04135287
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
Trial: NCT01988584
Drug: Saline Infusion (Placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.
Trial: NCT01695759
Drug: Eprex
RxNorm normalized name: Eprex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
Trial: NCT00759564
Drug: CP-70,429 and PF-03709270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
Trial: NCT03108846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masked placebo
Trial: NCT04162301
Drug: CS3002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.